FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:670-671 September 8, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Febrile, nonhemolytic reactions have been a clinical problem since the beginning of transfusion therapy. In the 1960s, antileukocyte antibodies were identified as a cause of these reactions, an observation that led to the discovery of the HLA antigens. The importance of antileukocyte antibodies has been shown by the Italian transfusion program for children with thalassemia, in which the use of leukocyte-depleted red cells virtually abolished febrile, nonhemolytic reactions¹. However, febrile transfusion reactions to red cells are not always due to antileukocyte antibodies. Therefore, it is still reasonable to allow two or three reactions to occur before a costly regimen . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Ness, P. M. (2000). Transfusion Medicine: An Overview and Update. Clin. Chem. 46: 1270-1276 [Abstract] [Full Text]